Characteristics of Madariaga and Venezuelan Equine Encephalitis Virus Infections, Panama

Luis Felipe Rivera, Carlos Lezcano-Coba, Jose Francisco Galué, Xacdiel Rodriguez, Yelissa Juarez, William M. de Souza, Zeuz Capitan-Barrios, Anayansi Valderrama, Leyda Abrego, Hector Cedeño, Carmela Jackman, Jesse J. Waggoner, Patricia V. Aguilar, Hilda Guzman, Scott C. Weaver, Robert B. Tesh, Sandra López-Vèrges, Christl A. Donnelly, Cassia F. Estofolete, Mauricio L. NogueiraNuno R. Faria, Nikos Vasilakis, Amy Y. Vittor, Darci R. Smith, Jean Paul Carrera

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Madariaga virus (MADV) and Venezuelan equine encephawere detected in Panama during 1961‒2023. We delitis virus (VEEV) are emerging arboviruses affecting rural scribed the clinical signs and symptoms and epidemiologic and remote areas of Latin America. However, clinical and characteristics of those cases, and also explored signs and epidemiologic reports are limited, and outbreaks are occur-symptoms as potential predictors of encephalitic alphavirus ring at an increasing frequency. We addressed the data gap infection compared with those of other arbovirus infections by analyzing all available clinical and epidemiologic data of occurring in the region. Our results highlight the challenges MADV and VEEV infections recorded since 1961 in Pan-for the clinical diagnosis of alphavirus disease in endemic ama. A total of 168 human alphavirus encephalitis cases regions with overlapping circulation of multiple arboviruses.

Original languageEnglish
Pages (from-to)S94-S104
JournalEmerging Infectious Diseases
Volume30
Issue number14
DOIs
StatePublished - Nov 2024

Bibliographical note

Publisher Copyright:
© 2024 Centers for Disease Control and Prevention (CDC). All rights reserved.

Funding

We thank Betsy Dutary, Julio Cisneros, Evelia Quiroz, and Mariana Garcia, who worked to develop laboratory dengue surveillance system and alphavirus surveillance. We thank Kathryn Hanley for support with study design and funding. This study was partially supported by the Armed Forces Health Surveillance Division, Global Emerging Infections Surveillance Branch, ProMIS ID no. P0052_23_NM awarded to D.R.S. J.P.C. is funded by the Clarendon Scholarship from the University of Oxford (grant no. SFF1920_CB2_MPLS_1293647). This work was supported by SENACYT (grant no. FID-2021-96 to J.P.C.); the National Institute of Allergy and Infectious Diseases, the National Institutes of Health (grant no. K08AI110528 to J.J.W.), the Centers for Research in Emerging Infectious Diseases Coordinating Research on Emerging Arboviral Threats Encompassing the NEOtropics (CREATE-NEO) (grant no. 1U01AI151807 awarded to N.V. and K.A.H.), and by the National Institutes of Health and the World Reference Center for Emerging Viruses and Arboviruses (NIH R24 AI120942 to S.C.W.). C.A.D. was supported by the NIHR HPRU in Emerging and Zoonotic Infections, a partnership between Public Health England, the University of Oxford, the University of Liverpool, and the Liverpool School of Tropical Medicine (grant no. NIHR200907). W.M.S. is supported by the Global Virus Network fellowship and the National Institutes of Health (grant no. AI12094) Global Virus Network fellowship, Burroughs Wellcome fund (no. 1022448), and Wellcome Trust-Digital Technology Development award, Climate Sensitive Infectious Disease Modelling (no. 226075/ Z/22Z). M.L.N. is a CNPq Research Fellow supported by a Fundação de Amparo à Pesquisa do Estado de São Paulo grant (no.22/03645-1). B.P.D. is a CNPq Research Fellow. N.R.F. acknowledges support from the Bill and Melinda Gates Foundation (no. INV034540), and Medical Research Council—Sao Paulo Research Foundation CADDE partnership award (no. MR/S0195/ 1 and FAPESP no. 18/14389-0). A.Y.V. acknowledges Research Command funding (contract no. NCRADANMRC-20-10993). This study was partially supported by the Armed Forces Health Surveillance Division, Global Emerging Infections Surveillance Branch, ProMIS ID no. P0052_23_NM awarded to D.R.S. J.P.C. is funded by the Clarendon Scholarship from the University of Oxford (grant no. SFF1920_CB2_MPLS_1293647). This work was supported by SENACYT (grant no. FID-2021-96 to J.P.C.); the National Institute of Allergy and Infectious Diseases, the National Institutes of Health (grant no. K08AI110528 to J.J.W.), the Centers for Research in Emerging Infectious Diseases Coordinating Research on Emerging Arboviral Threats Encompassing the NEOtropics (CREATE-NEO) (grant no. 1U01AI151807 awarded to N.V. and K.A.H.), and by the National Institutes of Health and the World Reference Center for Emerging Viruses and Arboviruses (NIH R24 AI120942 to S.C.W.). C.A.D. was supported by the NIHR HPRU in Emerging and Zoonotic Infections, a partnership between Public Health England, the University of Oxford, the University of Liverpool, and the Liverpool School of Tropical Medicine (grant no. NIHR200907). W.M.S. is supported by the Global Virus Network fellowship and the National Institutes of Health (grant no. AI12094) Global Virus Network fellowship, Burroughs Wellcome fund (no. 1022448), and Wellcome Trust-Digital Technology Development award, Climate Sensitive Infectious Disease Modelling (no. 226075/ Z/22Z). M.L.N. is a CNPq Research Fellow supported by a Fundação de Amparo à Pesquisa do Estado de São Paulo grant (no.22/03645-1). B.P.D. is a CNPq Research Fellow. N.R.F. acknowledges support from the Bill and Melinda Gates Foundation (no. INV034540), and Medical Research Council—Sao Paulo Research Foundation CADDE partnership award (no. MR/S0195/ 1 and FAPESP no. 18/14389-0). A.Y.V. acknowledges Research Command funding (contract no. NCRADA-NMRC-20-10993).

FundersFunder number
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Wellcome Trust-Digital
National Institute for Health Research Health Protection Research Unit
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...
Centers for Research in Emerging Infectious Diseases
Jiatong–Liverpool University
Liverpool School of Tropical MedicineAI12094, NIHR200907
National Institutes of Health (NIH)K08AI110528, R24 AI120942
Fundação de Amparo à Pesquisa do Estado de São Paulo18/14389-0, 22/03645-1, MR/S0195/ 1, NCRADA-NMRC-20-10993
CREATE-NEO1U01AI151807
Bill and Melinda Gates FoundationINV034540
UK Medical Research Council, Engineering and Physical Sciences Research CouncilMR/X020258/1
Climate Sensitive Infectious Disease Modelling226075/ Z/22Z
Armed Forces Health Surveillance DivisionP0052_23_NM
Oxford Martin School, University of OxfordSFF1920_CB2_MPLS_1293647
Burroughs Wellcome Fund1022448
Secretaría Nacional de Ciencia, Tecnología e InnovaciónFID-2021-96

    ASJC Scopus subject areas

    • Epidemiology
    • Microbiology (medical)
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Characteristics of Madariaga and Venezuelan Equine Encephalitis Virus Infections, Panama'. Together they form a unique fingerprint.

    Cite this